A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine

Author： Pascual Julio  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.3, 2004-03, pp. : 669-677

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine

By Dahlof C.   Lines C.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 671-685

Informa Healthcare

Access to resources Recommend Favorite

Cranial vascular effects of zolmitriptan, a centrally active 5-HT 1B/1D receptor partial agonist for the acute treatment of migraine

By MacLennan S.J.   Cambridge D.   Whiting M.V.   Marston C.   Martin G.R.  

European Journal of Pharmacology, Vol. 361, Iss. 2, 1998-11 ,pp. : 191-197

Elsevier

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT 1B/1D Receptor Agonist for the Treatment of Migraine

By McEnroe Janet D.   Fleishaker Joseph C.  

Clinical Pharmacokinetics, Vol. 44, Iss. 3, 2005-01 ,pp. : 237-246

Adis International

Access to resources Recommend Favorite

The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT 1B/1D receptor agonist

By Gupta P.   Butler P.   Shepperson N.B.   McHarg A.  

European Journal of Pharmacology, Vol. 398, Iss. 1, 2000-06 ,pp. : 73-81

Elsevier

Access to resources Recommend Favorite

Rizatriptan: A Pharmacoeconomic Review of its Use in the Acute Treatment of Migraine

By McCormack Paul L.   Foster Rachel H.  

PharmacoEconomics, Vol. 23, Iss. 12, 2005-01 ,pp. : 1283-1298

Adis International

Access to resources Recommend Favorite